Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508239 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP3A5GLSGPR119MEN1 | |
| SCHEMBL1852622 | 0.86 | GLS (0.57) | CYP3A4CYP3A5GLSGPR119MEN1 | |
| SCHEMBL5183732 | 0.85 | MEN1 (0.49) | CYP3A4CYP3A5GLSGPR119MEN1 | |
| SCHEMBL5184046 | 0.85 | ALDH1A1 (0.46) | CYP3A4CYP3A5GLSMEN1KMT2A | |
| SCHEMBL4883412 | 0.82 | CYP3A4 (0.52) | CYP3A4CYP3A5GLSGPR119MEN1 | |
| SCHEMBL13476475 | 0.81 | P2RX3 (0.48) | GLSGPR119ATMLMNANPC1 | |
| SCHEMBL14128435 | 0.79 | GPR119 (0.50) | CYP3A4CYP3A5GLSGPR119MEN1 | |
| SCHEMBL19668532 | 0.79 | CFTR (0.46) | CYP3A4CYP3A5GLSNPC1ALDH1A1 | |
| SCHEMBL19668681 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP3A5GLSGPR119 | |
| SCHEMBL29363322 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP3A5GLSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12454683-B2 | Modified archaeal family B polymerases | Singular Genomics Systems, Inc. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250283138-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| EP-4612127-A1 | BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019173760-A1 | BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3454907-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | Thetis Pharmaceuticals LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2018-07-19 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC | 2018-04-26 | — | — | US | disclosed |
| WO-2017210604-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | THETIS PHARMACEUTICALS LLC (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | PTGER1, PTGER4, PTGER2 | CYP3A4 1333/4885CYP3A5 1648/4885GLS 4055/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | CYP3A4 4157/4885CYP3A5 3367/4885GLS 226/4885 |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | CYP3A4 1352/4885CYP3A5 1149/4885GLS 1326/4885 |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | PBK, CD4, ICOS | CYP3A4 4727/4885CYP3A5 4665/4885GLS 3670/4885 |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | CYP3A4 4836/4885CYP3A5 4644/4885GLS 1050/4885 |
| US-20250283138-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | BCAT2, BCAT1, AADAT | CYP3A4 1815/4885CYP3A5 2412/4885GLS 65/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | CYP3A4 1356/4885CYP3A5 3108/4885GLS 309/4885 |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | CYP3A4 1352/4885CYP3A5 1149/4885GLS 1326/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | CYP3A4 2935/4885CYP3A5 3729/4885GLS 246/4885 |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | ALOX5, ALOX15, ALOX12 | CYP3A4 3818/4885CYP3A5 2681/4885GLS 2277/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | CYP3A4 3658/4885CYP3A5 2893/4885GLS 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.